The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of l-cysteine and l-cystine without increasing its toxicity. In particular, the combination of FT at 200 mg/kg per day (maximum dose) and 1000 mg/kg per day of l-cystine markedly inhibited tumor growth. The dose ratio of l-cysteine or l-cystine to FT needs 5 by weight to potentiate the antitumor activity of FT. The antitumor activity of 5-fluorouracil (FU) was slightly, but not significantly, increased by l-cysteine.
The total concentration of FT in the plasma and the tumor when it was given in combination with l-cystine was significantly increased when compared with FT alone 1 h after oral administration. The FU level in the plasma after administration of the combination of FT and l-cystine was three times higher than that after FT alone, and the FU level in the tumor after treatment with the combination of FT and l-cystine was also higher (about 20%) than that after FT alone.
This significant increase in FT and FU levels in the plasma and the tumor may be related to the potentiation of the antitumor activity of FT by l-cystine.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Au JL, Wu AT, Friedman MA, Sadée W (1979) Pharmacokinetics and metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil) in man. Cancer Treat Rep 63:343–350
Benvenuto JA, Lu K, Hall SW, Benjamin RS, Loo TL (1978) Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 38:3867–3870
Blokhina NG, Vozny EK, Garin AM (1972) Results of treatment of malignant tumors with ftorafur. Cancer 30:390–392
Chaudhuri NK, Mukherjee KL, Heidelberger C (1958) Studies on fluorinated pyrimidines VII-The degradative pathway. Biochem Pharmacol 1:328–341
Danysz A, Wierzba K, Wutkiewicz M, Pniewska A, Praglowski T, Burba-Anczewska I (1984) Influence of some sulfhydryl compounds on the antineoplastic effectiveness of 5-fluorouracil and 6-mercaptopurine. Arch Immunol Ther Exp 32:345–349
Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69:763–772
Fujii S, Kitano S, Ikenaka K, Fukushima M, Nakamura H, Maehara Y, Shirasaka T (1980) Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 71:100–106
Hiller SA, Zhuk RA, Lidak M, Ziederman A (1968) Analogues of pyrimidine nucleosides in chemotherapy of cancer. Presented at the First All-Union Conference on the Chemotherapy of Malignant Tumors, Riga, October, 7–11 B-1.2/3
Ichikawa Y, Yamano T (1967) Reconversion of detergent and sulfhydryl reagent produced P 420 to P-450 by polyols and glutathione. Biochim Biophys Acta 131:490–497
Iigo M, Hoshi A, Nakamura A, Kuretani K (1978) Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Cancer Chemother Pharmacol 1:203–208
Iigo M, Nakamura A, Kuretani K, Hoshi A (1980) Metabolic fate of 1-hexylcarbamol-5-fluorouracil after oral administration in mice. Xenobiotica 10:847–854
Kamataki T, Kitagawa H (1973) Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats. Biochem Pharmacol 22:3199–3207
Karev NI, Blokhina NG, Vozny EK, Pershin MP (1972) Experience with ftorafur treatment in breast cancer. Neoplasma 19:347–350
Ohira S, Maezawa S, Watanabe K, Kitada K, Sato T (1975) Experimental approach to increase the effect of cancer chemotherapy in tumor-bearing rats pretreated with an inducer on microsomal drug metabolizing enzyme (Cytochrome P 450). Ninth In ternational Congress of Chemotherapy, London
Remmer H, Merker HJ (1963) Drug-induced changes in the liver endoplasmic reticulum. Association with drug-metabolizing enzymes. Science 142:1657–1658
Saito T, Maezawa S (1979) Increased antitumor activity following stimulated activation of anticancer drugs (Masked compounds). Cancer Chemother 6:245–256
Toide H, Akiyoshi H, Minato Y, Okuda H, Fujii S (1977) Comparative studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Gann 68:553–560
Valdivieso M, Bodey GP, Gotlieb JA, Freireich EJ (1976) Clinical evaluation of ftorafur (pyrimidine-deoxyribose N1-2′-furanidyl-5-fluorouracil). Cancer Res 36:1821–1824
Wu AT, Au JL, Sadée W (1978) Hydroxylated metabolites of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in rats and rabbits. Cancer Res 38:210:214
Yoshimura K, Iwauchi Y, Sugiyama S, Kuwamura T, Odaka Y, Satoh T, Kitagawa H (1982) Transport of l-cysteine and reduced glutathione through biological membrane. Res Commun Chem Pathol Pharmacol 37:171–176
About this article
Cite this article
Iigo, M., Hoshi, A. & Kitagawa, H. Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with l-cystine. J Cancer Res Clin Oncol 111, 187–190 (1986). https://doi.org/10.1007/BF00389232
- Combination chemotherapy
- Antitumor activity